DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2016" report to their offering.
Metastatic Melanoma pipeline therapeutics constitutes close to 149 molecules. Out of which approximately 128 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 12, 50, 28, 1, 30 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 4, 6 and 2 molecules, respectively.
Metastatic Melanoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Metastatic Melanoma Overview
- Therapeutics Development
- Pipeline Products for Metastatic Melanoma - Overview
- Pipeline Products for Metastatic Melanoma - Comparative Analysis
- Metastatic Melanoma - Therapeutics under Development by Companies
- Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes
- Metastatic Melanoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Metastatic Melanoma - Products under Development by Companies
- Metastatic Melanoma - Products under Investigation by Universities/Institutes
- Metastatic Melanoma - Companies Involved in Therapeutics Development
- AB Science SA
- AbbVie Inc
- Adaptimmune Therapeutics Plc
- AGV Discovery, SAS
- Altor BioScience Corporation
- Amgen Inc.
- Angimmune LLC
- AstraZeneca Plc
- Basilea Pharmaceutica Ltd.
- Bristol-Myers Squibb Company
- Calithera Biosciences, Inc.
- Cellceutix Corporation
- Digna Biotech, S.L.
- Dynavax Technologies Corporation
- Eisai Co., Ltd.
- Eli Lilly and Company
- Ensol Biosciences Inc.
- F. Hoffmann-La Roche Ltd.
- Galapagos NV
- Galectin Therapeutics, Inc.
- GlaxoSmithKline Plc
- MELEMA Pharma GmbH
- Merck & Co., Inc.
- Millennium Pharmaceuticals Inc
- Modulate Therapeutics, Inc.
- Moleculin Biotech Inc
- Morphotek, Inc.
- NewLink Genetics Corporation
- Novartis AG
- Pfizer Inc.
- Pharmis Biofarmaceutica, Lda.
- Polaris Pharmaceuticals, Inc.
- Prima BioMed Ltd.
- TC BioPharm Limited
-
Tikcro Technologies, Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/zkvp68/metastatic
